ENDRA Life Sciences Faces Dire Q1'26 with Zero Revenue Estimate
NDRA sits 71% above its 52-week low of $2.9 on light trading volume (0.1× avg).
Summary
ENDRA Life Sciences Inc. is facing a critical Q1'2026, with analysts estimating zero revenue and an anticipated EPS of ($1.23). This dire forecast comes on the heels of the company's 2025 annual report, which highlighted significant financial distress, a going concern warning, and high Nasdaq delisting risk. The projected lack of revenue is a highly material development for this micro-cap company, indicating a severe absence of commercial activity and raising immediate concerns about its operational viability. Traders will be closely monitoring the official Q1'26 earnings release on May 18th for confirmation of these estimates and any strategic updates from management regarding the company's path forward.
At the time of this announcement, NDRA was trading at $4.95 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $6.1M. The 52-week trading range was $2.90 to $11.96. This news item was assessed with negative market sentiment and an importance score of 9 out of 10. Source: Wiseek News.